An interventional study of PET choline tracer in Hyperparathyroidism, sponsored by Jean-Mathieu Beauregard. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Jean-Mathieu Beauregard · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is primarily to make choline-PET clinically available at CHU de Québec - Université Laval, while assessing the safety of non-Health-Canada-approved choline tracers. Our hypothesis is that these tracers are safe, with a very low incidence of adverse events (AEs). The potential clinical impact of choline-PET will be explored in our clinical setting.
111 studies on the registry are indexed under Hyperparathyroidism; 13 are open to participants now.
This study's planned enrollment of 5,000 is above the median of 55 across 68 interventional studies indexed under Hyperparathyroidism.
Browse Hyperparathyroidism studies →Jean-Mathieu Beauregard is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PET choline tracer
Administration of a choline tracer for PET
Proportion of Participants with choline PET radiopharmaceuticals-Related Adverse Events as Assessed by CTCAE v5.0 .
From the moment the participants received the choline PET radiopharmaceuticals
Time frame: Up to 1 week
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2036, 120 months later.
Of 18 interventional studies with no phase under Hyperparathyroidism, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 46. This study's planned 120 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jean-Mathieu Beauregard